OT mobile menu

Search form


Hematologic Cancer Targets

Is Cytomegalovirus Linked to Childhood Leukemia Risk?

These findings suggest the possibility that ALL could be prevented with antiviral interventions or vaccination. Image © Jarun Ontakrai/Shutterstock.com 

Hematologic Cancer Targets

A follow-up analysis of the CheckMate-205 clinical trial found that nivolumab was associated with durable response rates in adults with relapsed or refractory Hodgkin lymphoma after ASCT.

An FLT3 inhibitor, gilteritinib, has been found to result in more frequent and sustained responses in patients with relapsed, refractory acute myeloid leukemia.

In this video, Gareth J. Morgan, MD, discusses the new biologic advances in multiple myeloma and how they are currently being applied to clinical practice.

Lenalidomide plus rituximab induction therapy followed by maintenance appears to provide favorable activity and a tolerable safety profile in follicular lymphoma patients who are double-refractory or had early relapse after initial diagnosis.

Anti-CD19 CAR T-cell therapy may benefit patients with aggressive B-cell non-Hodgkin lymphoma who have relapsed or are refractory to standard therapy.

CAR T-cell therapy may have a role in combating relapsed/refractory multiple myeloma, according to new data from a phase I study presented at the 2017 ASCO Annual Meeting, held June 2–6 in Chicago.

Brentuximab vedotin, a monoclonal antibody-drug conjugate, combined with gemcitabine may be a new treatment option for children and AYAs with relapsed or refractory Hodgkin lymphoma.


Subscribe to Hematologic Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.